-
According to a study published in the Oct. 23, 2003, New England Journal of Medicine, the Department of Veterans Affairs (VA) health care system has slashed the time veterans spend in
the hospital by half without sacrificing quality of patient care.
-
The Joint Commission on Accreditation of Healthcare Organizations has approved revised standards to help prevent the occurrence of deadly health care-associated infections (HAIs).
-
Access personnel at the University Hospital of Arkansas in Little Rock can look forward to moving up a recently established career ladder that is boosting morale as well as paychecks.
-
American Hospital Association attorney Lawrence Hughes said there are aspects of the privacy rule that still are not working well and are creating unnecessary burdens for hospitals, with little benefit to patients.
-
Does the security rule specify how a risk analysis must be conducted?; How should passwords be chosen to ensure security?; Can a home health agency post thank-you letters from patients on a bulletin board that can be seen by staff and other patients?
-
Integrating new automated dispensing technology with an already established computerized physician order-entry system (CPOE) has changed the way pharmacists work at El Camino Hospital, a community facility in Mountain View, CA. Freed from most dispensing duties, pharmacists now spend much of their time reviewing patient information before drugs are dispensed.
-
A combination of drugs is significantly more effective than either drug alone for preventing progression of benign prostatic hyperplasia (BPH), especially in high-risk men, according to a study appearing in the Dec. 17 issue of the New England Journal of Medicine.
-
Department of Health and Human Services Secretary Tommy G. Thompson has announced an interim final regulation for the Medicare Prescription Drug Discount Card Program.
-
Regular approval for another indication of imatinib mesylate (Gleevec) by Novartis Pharmaceuticals Corp. The FDA has granted imatinib mesylate (Gleevec) regular approval
-
Alefacept (Amevive), produced by Biogen, represents a new drug class for patients with chronic plaque psoriasis. The drug was approved by the U.S. Food and Drug Administration (FDA) on Jan. 31, 2003, and became available on Feb. 3, 2003.
